At this point, most people in the emergency medicine and critical care worlds just assume that balanced (ie, 1:1:1) transfusion is a proven intervention, and the focus has mostly moved on the the potential of whole blood. I am in an almost nonexistent minority when I argue that balanced transfusion is certainly not proven, and […]
The post No benefit from whole blood – the SWiFT trial appeared first on First10EM.
The article discusses medical practices related to blood transfusion for trauma patients experiencing severe bleeding. It focuses on the SWIFT trial, which compared the use of whole blood to individual blood components in these patients.
Historically, whole blood was used for transfusions. However, over time, component therapy became standard, allowing specific blood products like red blood cells, plasma, or platelets to be given as needed. There has been a renewed medical interest in whole blood for trauma, based on theories that it might offer a more complete and balanced resuscitation. Arguments for using whole blood include its natural ratios of red blood cells, plasma, and platelets, which some believe could improve blood clotting, reduce dilutional coagulopathy (a bleeding disorder from excessive fluid or components lacking clotting factors), and simplify administration by requiring fewer bags.
The SWIFT trial was a randomized study designed to compare low titer O positive or O negative whole blood to standard component therapy. It included adult trauma patients with significant bleeding. Patients received either whole blood or component therapy for the first six units of study products. The primary goal of the study was to measure death within 28 days.
The trial’s results showed no statistically significant difference in 28-day mortality between the two groups. Approximately 25.3 percent of patients in the whole blood group died, compared to approximately 26.6 percent in the component therapy group. There were also no significant differences in other measured outcomes. These included death within 24 hours, the need for massive transfusion, total blood product usage, or the occurrence of complications such as acute kidney injury, acute respiratory distress syndrome, or blood clot formation.
The article notes some limitations of the SWIFT trial. It was stopped early due to slow enrollment, which might have limited its ability to detect smaller differences. The median time to the first study product was relatively long (about 1.5 hours), meaning initial resuscitation often involved components before the study products were given. Also, the study design only used six units of whole blood before switching to components, which may not have been enough to show a sustained benefit.
In summary, the SWIFT trial did not provide evidence that whole blood offers a survival advantage over component therapy for severely injured trauma patients. While whole blood may have logistical advantages (such as fewer bags to administer), this study did not support its clinical superiority in improving survival. Therefore, component therapy remains the accepted standard of care.
https://first10em.com/no-benefit-from-whole-blood-the-swift-trial/
